drug
discoveri
industri
never
pressur
deliv
today
r
cost
spiral
higher
attrit
statist
clinic
develop
show
sign
improv
may
actual
get
wors
exampl
fda
highlight
march
drug
enter
phase
clinic
develop
year
less
like
reach
market
one
enter
clinic
develop
truism
much
fate
drug
candid
clinic
develop
embed
chemic
structur
henc
control
chemist
point
design
clearli
seriou
limit
drug
design
far
learnt
relationship
chemic
structur
attrit
clinic
develop
drug
design
everoptimist
hope
increas
understand
interact
drug
candid
protein
target
molecular
level
may
allow
qualiti
built
drug
candid
design
stage
inde
grow
number
target
tri
inhibit
activ
understand
relationship
inhibit
activ
target
molecular
level
pathophysiolog
effect
advanc
structur
molecular
biolog
well
biophys
led
determin
highresolut
atom
structur
mani
protein
target
drug
discoveri
project
instanc
kinas
target
well
valid
clinic
respect
role
inflamm
mani
highresolut
crystal
structur
avail
true
thrombin
antithrombosi
renin
hypertens
ino
inflamm
egf
receptor
tyrosin
kinas
cancer
well
mani
antibacteri
antivir
target
crystal
structur
import
drugmetabolis
enzym
also
known
potenti
enabl
structurebas
ration
optimis
potenc
select
metabol
howev
routin
control
potenc
select
metabol
base
use
structur
inform
yet
becom
realiti
highresolut
protein
structur
inform
deriv
nmr
spectroscopi
xray
crystallographi
structur
far
determin
crystallograph
method
applic
nmr
spectroscopi
routin
protein
structur
determin
limit
requir
larg
quantiti
solubl
multipli
label
protein
consider
time
limit
compar
small
protein
solidst
nmr
spectroscopi
appli
review
structur
model
design
compound
shown
map
contour
show
weak
densiti
around
put
posit
ethylamin
sidechain
andi
davi
gain
degre
chemistri
imperi
colleg
scienc
technolog
univers
london
phd
univers
huddersfield
professor
mi
page
studi
mechan
rearrang
penicillin
associ
director
physic
chemistri
astrazeneca
r
charnwood
astrazeneca
senior
princip
scientist
research
interest
energet
drugreceptor
interact
qsar
method
cooper
applic
physicalorgan
comput
chemistri
drug
discoveri
stephen
stgallay
read
chemistri
physic
manchest
univers
follow
phd
comput
chemistri
also
manchest
univers
sponsor
smithklin
beecham
later
gsk
investig
molecular
mechan
agon
antagon
human
adrenerg
receptor
join
boot
pharmaceut
later
knoll
pharmaceut
comput
chemistri
molecular
model
section
medicin
chemistri
work
cn
cancer
immun
antiobes
project
move
astra
later
astrazeneca
work
molecular
model
team
respiratori
inflamm
project
gerard
j
kleywegt
obtain
degre
chemistri
univers
leiden
netherland
doctor
univers
utrecht
work
autom
interpret
protein
nmr
spectra
short
time
biosym
join
alwyn
jone
protein
crystallographi
laboratori
uppsala
sweden
coordin
later
director
swedish
structur
biolog
network
sbnet
sinc
incept
award
fiveyear
research
fellowship
royal
swedish
academi
scienc
current
associ
professor
uppsala
univers
research
interest
includ
protein
crystallograph
method
develop
structur
bioinformat
protein
structur
work
remov
limit
molecular
size
still
infanc
word
reliant
xray
crystallographi
major
sourc
structur
inform
therefor
review
focus
upon
use
protein
proteinligand
structur
deriv
techniqu
use
xray
crystal
structur
designin
potenc
select
trivial
fraught
difficulti
ambigu
mislead
unwari
medicin
chemist
previous
highlight
limit
ambigu
use
xray
crystal
structur
ligand
drug
design
provid
hint
model
assess
valid
reliabl
crystal
structur
howev
literatur
still
abound
exampl
failur
surpris
warn
heed
drugdiscoveri
scientist
highlight
recent
exampl
hope
medicin
chemist
crystallograph
stimul
inform
fruit
dialogu
structur
inform
use
optim
drug
discoveri
protein
crystal
structur
use
structureguid
design
number
fundament
assumpt
commonli
made
protein
structur
correct
usual
assum
amino
acid
sequenc
known
correct
structur
model
includ
water
structur
complet
ie
entiti
miss
correct
known
high
accuraci
structur
ligand
interact
protein
correct
obviou
assumpt
chemic
composit
ligand
known
placement
activ
site
conform
correct
corollari
interact
receptor
ligand
known
understood
correct
proteinligand
structur
relev
drug
design
usual
tacitli
assum
condit
complex
crystallis
relev
observ
protein
conform
relev
interact
ligand
ie
flexibl
activesit
residu
structur
actual
contribut
insight
lead
design
better
compound
assumpt
seem
perfectli
reason
first
sight
necessarili
true
instead
assumpt
care
verifi
casebycas
basi
follow
section
also
refer
describ
recent
exampl
case
sever
assumpt
turn
invalid
act
warn
medicin
chemist
embark
structureguid
drugdesign
project
past
year
determin
crystal
structur
protein
dna
rna
virus
manner
complex
yield
fantast
insight
molecular
basi
myriad
biolog
system
process
howev
mani
scientist
use
structur
inform
seem
unawar
fact
xray
crystal
structur
one
crystallograph
subject
interpret
experiment
electron
densiti
map
express
term
atom
model
interpret
may
contain
error
may
complet
may
exist
altern
interpret
part
gener
resolut
studi
degre
experi
crystallograph
import
factor
determin
qualiti
final
model
deposit
worldwid
protein
data
bank
wwpdb
even
resolut
high
experiment
data
allow
model
structur
great
level
detail
may
still
part
structur
electron
densiti
poor
anoth
crystallograph
might
interpret
differ
resolut
low
probabl
error
incomplet
model
data
much
greater
nevertheless
chemist
undertak
structurebas
design
treat
protein
crystal
structur
rever
determin
high
resolut
regardless
resolut
structur
actual
determin
admittedli
crystallograph
immun
practic
either
also
fact
crystallograph
bound
made
certain
assumpt
certain
bias
perhap
even
made
mistak
usual
ignor
assumpt
bias
ambigu
mistak
may
manifest
even
highresolut
structur
level
individu
atom
residu
eg
sidechain
conform
beyond
gener
seriou
problem
less
often
occur
howev
even
day
age
occasion
happen
crystal
structur
publish
deposit
later
turn
serious
flaw
recent
retract
journal
scienc
five
paper
five
structur
wwpdb
code
msba
emr
atpbind
cassett
abc
transport
sent
shockwav
crystallograph
membran
protein
commun
fact
problem
model
came
light
structur
relat
protein
determin
show
structur
msba
emr
incorrect
shape
roughli
resembl
mirror
imag
correct
structur
case
unfortun
appear
incorrect
structur
seriou
advers
effect
develop
field
possibl
also
distribut
grant
money
locat
direct
connect
sever
transmembran
helic
incorrect
error
complet
invalid
infer
made
model
crystallograph
statist
indic
problem
caus
author
resort
inappropri
refin
protocol
although
softwar
error
may
caus
initi
problem
hard
see
alarm
bell
must
inevit
set
could
ignor
five
independ
structur
determin
especi
later
model
determin
higher
resolut
moreov
model
incompat
much
avail
biolog
data
unfortun
deposit
practic
crystallograph
journal
meant
first
model
ca
coordin
deposit
one
five
model
experiment
data
ever
deposit
mean
long
time
imposs
even
reproduc
electron
densiti
map
abctransport
structur
detail
technic
discuss
case
found
structur
staphylococcu
aureu
transcript
regul
sara
describ
natur
along
complex
sara
dna
wwpdb
code
respect
later
year
structur
homolog
protein
sarr
determin
independ
fusion
protein
maltosebind
protein
wwpdb
code
despit
homolog
sara
sarr
model
turn
significantli
dissimilar
model
apoform
sara
made
obsolet
ie
retract
wwpdb
model
dna
complex
remain
wwpdb
day
figur
unabl
identifi
followup
paper
origin
laboratori
address
issu
structur
sara
redetermin
resolut
wwpdb
code
laboratori
previous
solv
structur
sarr
sara
shown
expect
fold
similar
sarr
relat
protein
sar
marr
dramat
differ
earlier
sara
model
author
also
reproduc
crystal
saradna
complex
show
sara
fold
apoform
wwpdb
code
anoth
slightli
contenti
case
also
settl
recent
cocryst
structur
botulinum
neurotoxin
type
b
proteas
target
peptid
two
fragment
snare
protein
synaptobrevinii
report
resolut
year
wwpdb
code
year
later
seriou
question
rais
strength
experiment
evid
support
presenc
target
peptid
consequ
valid
infer
substrat
bind
matter
eventu
resolv
three
year
later
determin
complex
botulinum
neurotoxin
type
proteas
human
snare
protein
snap
wwpdb
code
structur
well
addit
calcul
see
supplementari
materi
show
origin
model
complex
incorrect
support
crystallograph
data
incorrect
model
retract
wwpdb
juli
origin
paper
yet
retract
quit
common
later
higher
resolut
structur
highlight
error
inadequaci
previous
determin
structur
structur
phenol
hydroxylas
determin
resolut
wwpdb
code
year
later
potenti
error
one
alreadi
identifi
origin
crystallograph
work
discov
sequenc
enzym
construct
sitedirect
mutant
subsequ
crystallograph
data
higher
resolut
collect
structur
refin
data
remain
sequenc
differ
turn
inde
error
sinc
new
residu
fit
densiti
much
better
incorrect
one
wwpdb
code
refin
higher
resolut
led
improv
free
r
valu
identif
new
featur
solvent
molecul
mainchain
shift
alter
sidechain
conform
interestingli
singl
largescal
error
old
model
differ
distribut
throughout
whole
model
appear
old
model
essenti
correct
complet
level
accuraci
accord
lower
resolut
data
may
worthwhil
revisit
rerefin
crystallograph
model
even
seriou
error
expect
origin
model
model
may
improv
latest
avail
refin
valid
rebuild
techniqu
use
cours
inclus
higher
resolut
data
fortun
case
almost
entir
protein
structur
model
incorrectli
rare
usual
occur
resolut
low
sensibl
procedur
model
build
refin
valid
jettison
howev
import
rememb
almost
everi
crystal
structur
even
atom
resolut
problemat
part
aspect
inspect
electron
densiti
togeth
model
prefer
presenc
crystallograph
may
help
identifi
part
assess
reliabl
model
area
particular
interest
bind
site
catalyt
residu
interact
motif
etc
februari
worldwid
protein
data
bank
amend
deposit
practic
requir
deposit
structur
factor
well
coordin
new
structur
mean
new
publicli
avail
structur
model
abl
view
experiment
data
deriv
interest
reader
obtain
inform
good
practic
valid
protein
structur
refer
tutori
avail
http
furthermor
one
keep
mind
highresolut
question
eg
pertain
nonbond
distanc
precis
posit
orient
conform
sidechain
interest
moieti
answer
reliabl
highresolut
data
avail
truism
even
season
crystallograph
need
remind
occasion
catrac
colourramp
blue
nterminu
red
cterminu
correct
structur
sara
protein
wwpdb
code
b
catrac
shown
orient
incorrect
model
protein
determin
six
year
earlier
wwpdb
code
ntermin
helix
colour
green
correct
secondari
structur
correct
sequenc
registr
two
yellow
helic
counterpart
correct
structur
sequenc
assign
incorrect
wwwdrugdiscoverytodaycom
structur
protein
known
crystallograph
model
ligand
complex
straightforward
alway
case
section
discuss
exampl
problem
may
aris
instanc
previous
describ
case
ligand
model
complex
enzym
later
found
absent
closer
inspect
electron
densiti
howev
opposit
situat
also
aris
frequent
name
densiti
entiti
either
retain
express
system
present
crystallis
soup
either
recognis
crystallograph
possibl
establish
chemic
ident
compound
mixtur
compound
peroxisom
proliferatoractiv
receptor
ppar
nuclear
receptor
fatti
acid
ligand
structur
ligandbind
domain
pparbd
determin
wwpdb
code
major
surpris
find
apoform
domain
display
essenti
conform
activ
ligandload
form
figur
year
ago
apostructur
redetermin
differ
laboratori
found
contain
mixtur
fatti
acid
acquir
bacteri
express
system
ligandbind
site
cisvaccen
acid
major
compon
wwpdb
code
observ
prompt
author
latter
work
reevalu
earlier
structur
use
origin
diffract
data
xu
et
al
highresolut
model
molecular
replac
probe
solv
refin
structur
anew
wwpdb
code
initi
electrondens
map
clearli
reveal
presenc
fatti
acid
bind
site
figur
densiti
ligand
probabl
cisvaccen
acid
well
origin
model
network
water
molecul
moreov
two
molecul
nheptylbdglucopyranosid
compound
import
crystallis
previous
overlook
identifi
densiti
reevalu
older
structur
sever
import
implic
first
conundrum
activ
conform
apo
structur
explain
second
previous
determin
bind
data
involv
protein
domain
must
treat
caution
unless
clear
fatti
acid
remov
analysi
third
fact
receptor
bind
endogen
fatti
acid
ligand
tightli
mean
possibl
exist
constitut
activ
previous
describ
care
crystallograph
model
refin
practic
sometim
help
detect
error
previous
gone
unnot
highthroughput
screen
compound
dihydrofol
reductas
compound
identifi
rel
potent
structur
unusu
inhibitor
figur
crystal
structur
complex
determin
electron
densiti
reveal
compound
could
readili
model
sinc
highresolut
data
collect
possibl
use
weak
anomal
signal
sulfur
atom
propos
compound
fact
compound
wwpdb
entri
hypothesi
subsequ
confirm
cnmr
method
also
support
sar
data
deriv
compound
inact
wherea
base
compound
show
signific
activ
holmner
et
al
describ
structur
hybrid
cholera
toxin
heatlabil
enterotoxin
complex
pentasaccharid
ligand
wwpdb
entri
drug
discoveri
today
volum
number
octob
electron
densiti
activ
site
assum
apoform
pparbd
model
sever
water
molecul
red
sphere
led
puzzl
conclus
apostructur
display
conform
activ
ligandbound
state
protein
wwpdb
code
b
reevalu
experiment
data
origin
studi
led
identif
bound
fatti
acid
ligand
cisvaccen
acid
suddenli
explain
earlier
conundrum
wwpdb
code
ligand
shown
gold
carbon
atom
residu
least
one
atom
within
ligand
atom
includ
residu
also
includ
electrondens
map
retriev
ed
shown
within
ligand
atom
ed
densiti
shown
within
ligand
atom
model
b
compound
actual
inhibitor
compound
put
inhibitor
dihydrofol
reductas
identifi
ht
ligand
assum
contain
nacetylglucosamin
unit
absenc
densiti
nacetyl
group
taken
indic
group
flexibl
howev
discov
later
ligand
fact
contain
glucos
unit
instead
presum
nacetylglucosamin
unit
wwpdb
entri
fortun
case
mistak
affect
conclus
drawn
structur
gener
crystallograph
model
oligosaccharid
appear
caus
particular
problem
crispin
et
al
report
third
structur
wwpdb
contain
oligosaccharid
signific
error
carbohydr
stereochemistri
nomenclatur
even
consist
electron
densiti
map
structur
even
contain
previous
unobserv
glycosid
linkag
incompat
known
biosynthet
rout
nglycan
process
clearli
highresolut
decis
assign
unusu
structur
featur
especi
incompat
known
chemistri
biolog
made
basi
lowresolut
electron
densiti
reason
ligand
gener
tend
model
much
less
accur
crystallograph
term
stereochemistri
geometri
amino
nucleic
acid
discuss
besid
paper
cite
section
exampl
ligand
poor
stereochemistri
wwpdb
also
discuss
refer
case
cite
section
exampl
seriou
mistak
hope
occur
often
howev
everyday
structurebas
design
context
problem
like
occur
good
awar
pitfal
mani
problem
discuss
previous
difficulti
involv
determin
orient
asparagin
glutamin
histidin
sidechain
assign
densiti
featur
water
molecul
problem
may
aris
densiti
ligand
poor
placement
ligand
crystallograph
question
perhap
debat
matter
fact
model
make
import
contribut
structur
determin
proteinligand
complex
first
knowledg
organ
chemistri
stereochemistri
small
molecul
often
better
protein
crystallograph
model
could
help
formul
appropri
refin
dictionari
proper
restraint
target
valu
bond
length
etc
second
knowledg
eye
judg
proteinligand
interact
could
help
crystallograph
propos
ligand
pose
fit
electron
densiti
make
good
sens
term
proteinligand
interact
widespread
avail
protein
structur
revolutionis
drug
discoveri
industri
wwpdb
contain
publicli
avail
structur
mani
avail
within
pharmaceut
compani
secret
vault
recent
breakthrough
structur
pharmaceut
import
membran
protein
also
becom
access
proteinligand
structur
even
spawn
new
drug
discoveri
paradigm
one
area
refractori
ration
design
lead
discoveri
fragmentbas
screen
use
crystal
structur
understand
thermodynam
protein
ligand
complex
still
develop
xray
crystal
structur
question
confront
understand
opportun
develop
learn
condit
crystallis
often
assum
absolut
relev
condit
biolog
assay
howev
chang
buffer
constitu
ph
crystallis
condit
profound
effect
conform
ligand
protein
instanc
sever
acut
respiratori
syndrom
sar
coronaviru
main
proteas
crystallis
differ
ph
valu
complex
specif
inhibitor
structur
reveal
substanti
phdepend
conform
chang
unexpect
mode
bind
substrateanalogu
inhibitor
ph
valu
structur
monom
homodim
differ
one
activ
inact
conform
inhibitor
bind
differ
mode
monom
often
assum
least
singl
composit
mother
liquor
independ
whether
complex
form
soak
cocrystallis
singl
reproduc
crystal
structur
determin
howev
recent
studi
aldos
reductas
complex
tolrestat
zopolrestat
highlight
assumpt
necessarili
valid
author
observ
flip
peptid
bond
depend
whether
zopolrestat
soak
cocrystallis
peptid
flip
result
ruptur
key
hydrogen
bond
ligand
tolrestat
ligand
complex
two
differ
stoichiometri
obtain
one
one
one
four
inhibitor
molecul
bound
accommod
four
ligand
caus
appreci
shift
two
helic
interact
addit
ligand
exampl
two
differ
bind
mode
observ
chemic
similar
ligand
provid
crystal
structur
e
coli
ketopanto
reductas
complex
phosphoadpribos
fragment
nadp
lack
nicotinamid
ring
attempt
crystallis
ternari
complex
enzym
pantoat
nadph
crystal
obtain
densiti
show
trace
pantoat
fragment
nadph
could
locat
fragment
confirm
phosphoadpribos
massspectrometri
experi
compar
complex
nadp
ligand
bind
opposit
orient
isotherm
titrat
calorimetri
sever
mutant
show
unusu
bind
mode
caus
chang
proton
state
bind
group
low
ph
implic
observ
fragmentbas
approach
ligand
design
bind
mode
may
alter
profoundli
variat
crystallis
condit
well
unexpect
intent
modif
ligand
effect
protein
flexibl
small
least
understood
number
review
stress
import
protein
flexibl
proteinligand
interact
protein
flexibl
induc
ligand
bind
address
real
problem
predict
model
also
real
opportun
drugdesign
purpos
increas
number
paper
publish
describ
attempt
incorpor
protein
flexibl
model
consequ
model
protein
flexibl
dock
virtualscreen
applic
account
protein
flexibl
pharmacophor
model
base
multipl
conform
protein
studi
model
proteas
singl
ensembl
nmr
model
found
display
structur
variat
collect
crystal
structur
pharmacophor
model
base
either
set
structur
work
well
discrimin
true
decoy
inhibitor
model
base
nmr
ensembl
appear
accur
yet
gener
represent
activ
site
clear
whether
increas
structur
variat
nmr
ensembl
reflect
model
true
dynam
underdetermin
structur
data
nevertheless
use
diffus
protein
model
would
appear
benefici
virtualscreen
applic
surpris
ligandinduc
conform
chang
continu
report
even
protein
activ
site
studi
extens
mani
crystal
structur
avail
surpris
still
occur
provid
opportun
medicin
chemistri
exploit
instanc
well
known
human
aldos
reductas
possess
two
main
bind
pocket
rigid
anionbind
pocket
flexibl
hydrophob
pocket
open
close
depend
bound
ligand
henc
surpris
find
potent
ligand
naphthol
isothiazol
acet
acid
seri
extend
anionbind
site
open
new
subpocket
model
two
seri
adenosin
kinas
inhibitor
prove
confus
expect
bind
mode
predict
model
studi
fail
predict
observ
structureact
relationship
chemic
similar
adenosin
bind
similar
fashion
enzym
new
seri
alkynylpyrimidin
inhibitor
assum
bind
pyrimidin
ring
orient
way
howev
crystal
structur
complex
determin
found
alkynylpyrimidin
compound
display
distinctli
differ
bind
mode
adenosinekinas
structur
accommod
inhibitor
rotat
small
domain
rel
larg
domain
inhibitor
bind
opposit
manner
expect
previous
suggest
hydrophob
residu
might
play
import
role
ligandinduc
conform
chang
protein
activ
site
hypothesi
recent
confirm
analysi
highresolut
apoholo
structur
pair
pair
display
littl
conform
chang
upon
ligand
bind
moder
degre
induc
fit
substanti
chang
ligand
bind
pocket
undergo
signific
conform
chang
tend
domin
polar
activ
site
residu
hydrogenbond
interact
bind
pocket
undergo
ligandinduc
conform
alter
hand
found
hydrophob
natur
tryptophan
high
propens
occur
flexibl
activ
site
structur
use
design
potent
ligand
even
highresolut
xray
crystal
structur
necessarili
aid
design
potent
ligand
observ
interact
crystal
structur
provid
inform
thermodynam
form
interact
silverman
cowork
design
hydroxyl
aminosubstitut
arginin
analogu
peptidomimet
inhibitor
neuron
nitric
oxid
synthas
nno
crystal
structur
analysi
reveal
presenc
import
structur
water
molecul
hydrogenbond
two
propion
moieti
no
haem
group
figur
c
molecular
model
led
design
nhydroxi
namino
analogu
shown
crystallographi
success
displac
activesit
water
molecul
fail
improv
vitro
potenc
significantli
figur
c
hydrogen
bond
propion
group
caus
small
displac
ligand
weaken
hydrogenbond
interact
protein
model
studi
suggest
hydrogenbond
group
h
isoquinolin
inhibitor
phenethanolamin
nmethyltransferas
would
confer
increas
potenc
howev
compound
synthesis
actual
less
activ
parent
hsubstitut
analogu
author
suggest
illustr
limit
extent
predict
base
dock
studi
employ
guid
chemistri
free
energi
bind
result
larg
chang
enthalpi
entropi
system
observ
proteinligand
complex
one
part
whole
system
compris
unbound
ligand
protein
bound
ligandprotein
complex
bulk
solvent
reorganis
ligand
bind
displac
solvent
molecul
apoprotein
activ
site
observ
interact
crystal
structur
provid
inform
overal
thermodynam
chang
system
undergon
analysi
structur
inform
help
least
unravel
unusu
thermodynam
observ
sever
recent
studi
demonstr
complex
subtleti
thermodynam
drugligandreceptor
interact
hydrogen
bond
ligand
protein
often
seen
import
enthalpydriven
interact
facilit
specif
select
hydrophob
interact
yield
signific
increas
affin
well
often
view
nonspecif
entropydriven
howev
detail
calorimetr
studi
found
mani
exampl
enthalpydriven
hydrophob
interact
well
hydrogen
bond
form
ligand
protein
entropydriven
homan
analys
hydrophob
bind
ligand
mous
urinari
conclud
suboptim
hydrat
protein
bind
site
caus
exchang
hydrophob
ligand
solvent
becom
enthalpydriven
owe
favour
solutesolut
dispers
forc
lead
signific
gain
bind
affin
shape
complementar
optimis
klebe
shown
even
seemingli
trivial
structur
homolog
highlight
surpris
complex
structureact
relationship
pair
thrombin
inhibitor
hydrophob
bind
group
homolog
cyclopentyl
cyclohexyl
gave
ident
bind
affin
instead
expect
increas
affin
kjmol
incorpor
addit
methylen
unit
xray
crystallographi
show
cyclopentyl
group
gave
good
densiti
pocket
cyclohexyl
compound
show
illdefin
densiti
differ
map
interpret
either
static
dynam
disord
cyclohexyl
group
itc
reveal
equal
gibb
free
energi
two
inhibitor
factor
differ
enthalp
entrop
contribut
free
energi
bind
cyclopentyl
compound
factor
equal
entropi
enthalpi
cyclohexyl
compound
show
rel
larger
entrop
advantag
bind
compens
weaker
enthalp
contribut
bind
consist
observ
crystallographi
high
residu
mobil
cyclohexyl
group
result
loss
good
enthalp
contact
compens
smaller
entropi
penalti
paid
enthalpyentropi
compens
gener
observ
phenomenon
reflect
interplay
enthalp
benefit
tight
interact
entrop
price
paid
form
still
surpris
subtl
medicin
chemistri
chang
result
larg
unpredict
chang
biophys
system
perfect
compens
xray
crystal
structur
ligand
bound
target
protein
seduct
clariti
exampl
given
section
highlight
thermodynam
system
may
confound
simpl
straightforward
interpret
base
xray
crystal
model
surpris
highlight
discrep
expect
structureact
relationship
observ
xray
crystal
structur
import
opportun
gain
detail
understand
underli
physic
system
combin
xray
crystal
structur
inform
molecular
dynam
simul
calorimetr
investig
start
unravel
subtl
complex
surpris
also
provid
potenti
gain
chemic
novelti
drug
discoveri
programm
henc
one
embrac
surpris
opportun
rather
interest
academ
distract
astrazeneca
project
discov
inhibitor
induc
nitric
oxid
synthas
ino
potenti
treatment
inflammatori
diseas
demonstr
limit
xray
crystallographi
model
compound
design
highlight
review
seri
compound
exist
promis
potenc
select
sever
proteinligand
structur
exist
ligand
complex
oxygenas
domain
mous
ino
select
ino
two
constitut
activ
isoform
neuron
no
import
gut
motil
longterm
memori
epitheli
no
import
maintain
vascular
tone
key
requir
potenti
designin
select
ino
nno
eno
inhibit
appear
quit
challeng
amino
acid
side
chain
differ
within
activ
site
asp
ino
asn
eno
asp
mous
ino
exist
ligand
make
interact
ino
asp
residu
henc
compound
design
strategi
buildin
interact
residu
hope
would
engend
increas
ino
potenc
select
eno
programm
grid
use
analys
activ
site
suggest
favour
posit
basic
nitrogen
atom
one
featur
grid
consid
benefit
make
interact
cost
displac
activesit
water
molecul
compound
bear
benzylamin
substitu
design
place
basic
nitrogen
within
favour
grid
densiti
wwwdrugdiscoverytodaycom
basic
nitrogen
atom
bind
mode
compound
predict
use
programm
gold
indic
possibl
build
interact
basic
nitrogen
side
chain
maintain
bind
mode
demonstr
exist
compound
chemic
seri
figur
howev
synthesis
test
activ
compound
found
much
lower
predict
fact
worst
seri
structureact
relationship
show
interact
base
acid
side
chain
dramat
reduc
potenc
tabl
xray
structur
determin
design
compound
complex
ino
although
low
resolut
inspect
structur
model
seem
confirm
bind
mode
predict
gold
interact
base
figur
puzzl
undermin
confid
comput
chemistri
tool
variou
hypothes
develop
explain
drop
potenc
benzylamin
compound
appar
bind
exactli
predict
crystal
structur
water
molecul
often
observ
hydrogen
bond
could
displac
interestingli
displac
carboxyl
group
nativ
ligand
arginin
suggest
either
asp
ligand
acid
group
proton
proton
might
account
poor
potenc
design
compound
strong
salt
bridg
form
hydrogen
atom
ad
water
molecul
protein
complex
energi
minimis
three
good
hydrogen
bond
observ
water
molecul
protein
hypothesis
displac
water
molecul
ligand
result
loss
hydrogen
bond
gain
caus
loss
potenc
final
hypothesi
solvat
energi
penalti
remov
benzyl
amin
compound
solut
balanc
interact
energi
amin
protein
combin
three
consider
might
respons
poor
potenc
compound
bind
conform
predict
final
chapter
stori
occur
prepar
public
exampl
weak
current
comput
chemistri
tool
manuscript
fulli
prepar
readi
submiss
second
crystallograph
analys
electron
densiti
sinc
origin
crystallograph
left
compani
opinion
second
crystallograph
data
good
enough
support
posit
amin
substitu
design
compound
interact
side
chain
origin
suggest
electron
densiti
ethylamin
chain
weak
owe
resolut
detail
enough
distinguish
water
molecul
figur
effort
made
recollect
data
complex
without
success
case
studi
reinforc
mani
lesson
highlight
earlier
chief
among
import
good
commun
medicin
chemistri
comput
chemistri
structur
chemistri
interpret
result
drug
discoveri
today
volum
number
octob
mous
ino
protein
green
complex
gold
dock
design
compound
yellow
xray
structur
compound
purpl
grid
densiti
probe
cation
nitrogen
contour
level
leau
shown
blue
grid
red
grid
show
probe
unfavour
compar
water
molecul
contour
level
leau
note
red
densiti
region
amin
design
interact
crystallographi
inspect
crystal
model
electron
densiti
map
detail
compound
design
decis
made
number
softwar
packag
freeli
avail
internet
visualis
crystal
structur
model
togeth
electron
densiti
includ
astex
viewer
correct
interpret
origin
data
could
help
draw
conclus
interact
weak
would
certainli
save
lot
futil
deep
thought
hypothesi
gener
inde
medicin
chemistri
design
synthesi
xray
crystal
structur
realli
aid
drug
design
structurebas
design
deliv
drug
market
number
import
diseas
includ
cancer
hiv
glaucoma
hypertens
recent
protein
renin
final
succumb
ration
drug
design
aliskiren
first
renin
inhibitor
reach
market
almost
two
decad
research
global
pharmaceut
industri
target
mechan
control
hypertens
pharmaceut
industri
continu
invest
collect
protein
structur
inform
aid
drug
design
ideal
case
use
protein
structur
model
use
designin
potenc
select
drug
design
requir
much
mani
properti
need
built
chemic
structur
directli
aid
may
even
hinder
avail
protein
structur
model
instanc
pharmaceut
industri
recognis
number
year
ago
import
physicochem
properti
gain
oral
bioavail
recent
work
suggest
physicochem
properti
control
even
wider
import
inflat
lipophil
molecular
weight
hydrogen
bond
interact
reduct
solubl
link
poor
oral
bioavail
also
unwant
metabol
number
sever
offtarget
activ
variou
toxicolog
endpoint
even
overal
attrit
clinic
develop
drug
design
requir
care
control
properti
maintain
high
target
affin
previous
suggest
use
protein
structur
inform
entic
medicin
chemist
inflat
lipophil
hydrogen
bond
interact
molecular
weight
fill
protein
pocket
maximis
interact
ligand
protein
interfac
protein
structur
inform
may
use
differ
way
may
allow
ration
replac
undesir
function
group
made
posit
physic
propertycontrol
group
solvent
capitalis
protein
movement
captur
differ
protein
pharmacophor
identif
highli
ligand
effici
motif
use
xray
crystal
structur
model
continu
prove
valuabl
drug
discoveri
model
provid
strong
stimulu
chemic
creativ
direct
visualis
ligandreceptor
interact
interact
otherwis
rather
abstract
medicin
chemist
whose
altern
blindli
feel
way
forward
use
tool
structureact
analysi
user
xray
crystal
structur
inform
howev
import
realis
crystal
structur
model
crystallograph
partli
subject
interpret
experiment
data
interpret
may
flaw
ambigu
inaccur
detail
rare
case
entireti
best
way
assess
reliabl
model
discuss
crystallograph
produc
examin
model
alongsid
experiment
electron
densiti
put
model
test
iter
structureact
work
